-
Notifications
You must be signed in to change notification settings - Fork 0
/
Copy pathtarget_list.txt
160 lines (160 loc) · 19.3 KB
/
target_list.txt
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
https://www.cff.org/Trials/Finder/details/534/Phase-3-study-of-lumacaftor-ivacaftor-Orkambi-in-babies-with-two-copies-of-the-F508del-CFTR-mutation
https://www.cff.org/Trials/Finder/details/536/Phase-2-study-of-PTI-428-drug-in-people-with-CF-ages-18-and-older-who-have-two-copies-of-the-F508del-CFTR-mutation
https://www.cff.org/Trials/Finder/details/508/Phase-1-study-of-PTI-808-drug-and-triple-combination-in-healthy-adults-and-then-in-adults-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/504/RESTORE-CF-Phase-1-2-study-of-MRT5005-drug-in-adults-with-cystic-fibrosis-Parts-A-B
https://www.cff.org/Trials/Finder/details/497/Phase-3-study-of-long-term-ivacaftor-in-babies-who-have-a-CFTR-gating-mutation
https://www.cff.org/Trials/Finder/details/491/Phase-1-2-study-of-PTI-801-drug-in-healthy-adults-and-then-in-adults-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/452/Phase-3-study-of-ivacaftor-in-babies-who-have-a-CFTR-gating-mutation
https://www.cff.org/Trials/Finder/details/542/SHIP-CT-Study-of-hypertonic-saline-in-preschoolers
https://www.cff.org/Trials/Finder/details/515/Phase-2-study-of-lenabasum-in-people-with-CF-ages-12-and-older
https://www.cff.org/Trials/Finder/details/448/Phase-2-study-of-LAU-7b-in-adults-with-CF-APPLAUD
https://www.cff.org/Trials/Finder/details/466/Phase-3-study-of-inhaled-vancomycin-in-adults-and-children-6-years-and-older-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/377/Phase-2-study-of-inhaled-nitric-oxide-in-people-with-CF
https://www.cff.org/Trials/Finder/details/455/STOP-2-Treatment-of-pulmonary-exacerbations-in-people-with-CF
https://www.cff.org/Trials/Finder/details/432/TEACH-Testing-the-effect-of-adding-oral-azithromycin-to-inhaled-tobramycin-in-people-with-CF
https://www.cff.org/Trials/Finder/details/544/OPTION-Study-of-AzurRx-MS1819-in-people-with-cystic-fibrosis-and-exocrine-pancreatic-insufficiency-who-are-18-years-and-older
https://www.cff.org/Trials/Finder/details/503/PREDICT-NTM-observational-study-
https://www.cff.org/Trials/Finder/details/506/Sweat-chloride-observational-study
https://www.cff.org/Trials/Finder/details/477/Rare-mutation-cell-collection-RARE
https://www.cff.org/Trials/Finder/details/519/Phase-3-study-of-VX-445-triple-combination-drug-in-people-with-CF-ages-12-years-and-older-who-have-two-copies-of-the-F508del-mutation
https://www.cff.org/Trials/Finder/details/517/Phase-3-study-of-VX-445-triple-combination-drug-in-people-with-CF-12-years-and-older-who-have-one-copy-of-the-F508del-mutation-and-one-copy-of-a-minimal-function-mutation
https://www.cff.org/Trials/Finder/details/518/Phase-3-study-of-VX-659-triple-combination-drug-in-people-with-CF-ages-12-years-and-older-who-have-two-copies-of-the-F508del-mutation
https://www.cff.org/Trials/Finder/details/516/Phase-3-study-of-VX-659-triple-combination-drug-in-people-with-CF-12-years-and-older-who-have-one-copy-of-the-F508del-mutation-and-one-copy-of-a-minimal-function-mutation
https://www.cff.org/Trials/Finder/details/480/A-study-to-evaluate-tezacaftor-ivacaftor-and-ivacaftor-in-adults-with-cystic-fibrosis-and-two-copies-of-the-F508del-mutation
https://www.cff.org/Trials/Finder/details/489/Phase-2-study-of-VX-659-combination-drug-in-adults-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/478/Phase-2a-study-of-Galapagos-GLPG2222-in-adults-with-CF
https://www.cff.org/Trials/Finder/details/445/Phase-2-study-of-CTP-656-in-adults-with-CF-who-are-currently-taking-ivacaftor-Kalydeco
https://www.cff.org/Trials/Finder/details/462/Phase-3-study-of-tezacaftor-VX-661-combination-drug-in-children-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/460/SNO7-Phase-2-study-of-N91115-in-adults-with-CF-who-are-currently-taking-ivacaftor
https://www.cff.org/Trials/Finder/details/413/Phase-2-study-of-Vertex-661-and-ivacaftor-in-adults-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/386/Phase-1-exploratory-study-on-the-effect-of-the-drug-QR-010-on-nasal-cells
https://www.cff.org/Trials/Finder/details/421/SNO6-Phase-2-study-of-N91115-in-adults-with-CF-who-are-currently-taking-lumacaftor-ivacaftor
https://www.cff.org/Trials/Finder/details/385/Phase-1b-safety-study-of-QR-010-in-adults-with-CF
https://www.cff.org/Trials/Finder/details/362/Phase-2-study-of-riociguat-in-adults-with-CF
https://www.cff.org/Trials/Finder/details/370/Phase-2-study-of-Vertex-661-770-in-people-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/422/Cohorts-1-and-2-of-a-study-to-evaluate-inhaled-QBW276-in-adults-with-CF
https://www.cff.org/Trials/Finder/details/471/Phase-1b-study-of-inhaled-AZD5634-in-adults-with-CF
https://www.cff.org/Trials/Finder/details/391/SHIP-Study-of-hypertonic-saline-in-preschoolers
https://www.cff.org/Trials/Finder/details/424/Phase-2-study-of-GS-5745-in-adults-with-CF
https://www.cff.org/Trials/Finder/details/384/Phase-2-study-of-CTX-4430-in-people-with-CF-EMPIRE
https://www.cff.org/Trials/Finder/details/395/Phase-2-study-of-JBT-101-in-people-with-CF
https://www.cff.org/Trials/Finder/details/355/Tobramycin-Inhalation-Powder-TIP-in-People-with-Cystic-Fibrosis-Extension-Study
https://www.cff.org/Trials/Finder/details/327/AeroVanc-for-the-treatment-of-MRSA-in-people-with-CF
https://www.cff.org/Trials/Finder/details/148/Arikace-compared-to-TOBI-in-people-with-CF-with-chronic-Pseudomonas-aeruginosa-infections
https://www.cff.org/Trials/Finder/details/185/Inhaled-Levofloxacin-MP-376-pediatric-safety-study
https://www.cff.org/Trials/Finder/details/490/RESULT-Study-of-liprotamase-non-porcine-enzymes
https://www.cff.org/Trials/Finder/details/441/Phase-2-study-of-oral-glutathione-in-children-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/449/SIMPLICITY-Phase-3-study-of-liprotamase-in-people-with-CF-related-pancreatic-insufficiency
https://www.cff.org/Trials/Finder/details/284/Vitamin-D-for-enhancing-the-immune-system-in-people-with-CF
https://www.cff.org/Trials/Finder/details/457/Phase-4-study-of-adherence-to-lumacaftor-ivacaftor-in-people-with-CF
https://www.cff.org/Trials/Finder/details/353/Phase-4-TOBI-Podhaler-observational-study
https://www.cff.org/Trials/Finder/details/375/PROSPECT
https://www.cff.org/Trials/Finder/details/430/GOAL-e2-Lung-Clearance-Index-Study-in-Children-3-to-5-Years-Old-who-have-a-CFTR-gating-mutation
https://www.cff.org/Trials/Finder/details/261/Porcine-viral-antibody-point-prevalence-study-in-people-with-CF-taking-pancreatic-enzymes
https://www.cff.org/Trials/Finder/details/342/An-Ocular-Safety-Study-of-Kalyedeco-Treated-Children-11-Years-of-Age-or-Younger-with-CF
https://www.cff.org/Trials/Finder/details/265/Phase-4-study-to-monitor-the-susceptibility-of-Pseudomonas-aeruginosa-to-aztreonam-in-people-with-CF
https://www.cff.org/Trials/Finder/details/125/Prediction-by-Ultrasound-of-the-Risk-of-Hepatic-Cirrhosis-in-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/549/Phase-3-study-of-ivacaftor-in-babies-12-24-month-old-who-have-a-CFTR-gating-mutation
https://www.cff.org/Trials/Finder/details/492/Phase-1-2-study-of-VX-445-combination-drug-in-healthy-adults-and-then-in-people-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/406/Phase-3-study-of-Vertex-661-and-ivacaftor-in-people-with-CF-who-have-one-copy-of-the-F508del-CFTR-mutation-and-a-second-CFTR-mutation-predicted-to-have-residual-function
https://www.cff.org/Trials/Finder/details/343/VX-809-and-ivacaftor-in-people-with-CF-who-are-aged-12-years-and-older-and-have-two-copies-of-the-F508del-CFTR-mutation-105
https://www.cff.org/Trials/Finder/details/399/Vertex-Lumacaftor-VX-809-and-Ivacaftor-in-Children-with-CF-aged-6-to-11-years-and-have-two-copies-of-the-delF508-CFTR-mutation
https://www.cff.org/Trials/Finder/details/459/Phase-2-study-of-VX-440-combination-drug-in-people-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/458/Phase-2-study-of-VX-152-combination-drug-in-people-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/469/Phase-3-study-of-lumacaftor-ivacaftor-in-children-with-CF
https://www.cff.org/Trials/Finder/details/405/Phase-3-study-of-Vertex-661-and-ivacaftor-in-people-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/400/Phase-3-study-of-lumacaftor-and-ivacaftor-in-children-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/407/Phase-3-study-of-Vertex-661-and-ivacaftor-in-people-with-CF-who-have-one-copy-of-the-F508del-CFTR-mutation-and-a-second-CFTR-mutation-with-a-gating-defect-responsive-to-ivacaftor
https://www.cff.org/Trials/Finder/details/394/Phase-3-study-of-lumacaftor-and-ivacaftor-in-with-cystic-fibrosis-with-advanced-lung-disease
https://www.cff.org/Trials/Finder/details/388/SNO4-Study-of-N91115-in-people-with-cystic-fibrosis-ages-18-and-older-with-two-copies-of-F508del-CFTR-mutation
https://www.cff.org/Trials/Finder/details/402/Phase-3-study-of-VX-661-and-ivacaftor-in-people-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/361/Phase-3-study-of-Ataluren-in-people-with-CF-who-have-a-nonsense-mutation-and-are-not-taking-aminoglycosides
https://www.cff.org/Trials/Finder/details/209/Vertex-809-770-in-People-with-Cystic-Fibrosis-and-F508del-CFTR-mutation
https://www.cff.org/Trials/Finder/details/340/Vertex-Lumacaftor-VX-809-and-Ivacaftor-in-People-with-CF-aged-12-years-and-older-and-have-two-copies-of-the-delF508-CFTR-mutation-TRANSPORT
https://www.cff.org/Trials/Finder/details/328/Vertex-Lumacaftor-VX-809-and-ivacaftor-in-people-with-CF-who-are-aged-12-years-and-have-two-copies-of-the-delF508-CFTR-mutation-TRAFFIC
https://www.cff.org/Trials/Finder/details/326/SNO1-Study-of-N6022-in-people-with-CF
https://www.cff.org/Trials/Finder/details/288/Ivacaftor-in-People-with-CF-age-2-to-5-years-with-a-CFTR-Gating-Mutation
https://www.cff.org/Trials/Finder/details/287/Ivacaftor-in-People-with-CF-who-have-a-Non-G551D-Gating-Mutation-KONNECTION
https://www.cff.org/Trials/Finder/details/286/Ivacaftor-in-People-with-CF-who-have-the-R117H-CFTR-mutation-KONDUCT
https://www.cff.org/Trials/Finder/details/282/VX-661-alone-and-in-combination-with-ivacaftor-in-people-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/277/VX-770-Expanded-Access-Program
https://www.cff.org/Trials/Finder/details/245/Vertex-770-a-phase-2-trial-evaluating-the-effect-of-VX-770-on-Lung-Clearance-Index
https://www.cff.org/Trials/Finder/details/207/VX-770-in-People-with-CF-and-G551D-Mutation-Open-Label-Safety-Study-PERSIST
https://www.cff.org/Trials/Finder/details/15/VX-770-Phase-2-study-in-People-with-CF-and-Genotype-G551D
https://www.cff.org/Trials/Finder/details/184/Vertex-770-in-People-with-CF-with-Homozygous-Delta-F508-Mutation-DISCOVER
https://www.cff.org/Trials/Finder/details/87/Vertex-770-and-the-G551D-mutation-STRIVE
https://www.cff.org/Trials/Finder/details/177/Vertex-770-in-Children-with-CF-and-the-G551-Mutation-ENVISION
https://www.cff.org/Trials/Finder/details/84/Ataluren-PTC-124-in-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/86/Safety-Study-of-VX-809-in-People-with-CF-and-Homozygous-for-Delta-F508-Gene-Mutation
https://www.cff.org/Trials/Finder/details/26/Pulmozyme-in-3-5-Year-Old-Children-with-CF
https://www.cff.org/Trials/Finder/details/444/Phase-2-study-of-VX-371-in-people-with-CF-who-are-currently-taking-lumacaftor-ivacaftor
https://www.cff.org/Trials/Finder/details/396/Clearing-Lungs-With-ENAC-Inhibition-in-Cystic-Fibrosis-CLEAN-CF
https://www.cff.org/Trials/Finder/details/360/Phase-3-study-of-inhaled-mannitol-in-adults-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/237/Denufosol-in-People-with-CF-ages-2-4-years
https://www.cff.org/Trials/Finder/details/71/Inhaled-Dry-Powder-Mannitol-in-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/7/Denufosol-Inhalation-Solution-for-People-with-CF-and-Mild-Lung-Disease-TIGER-1
https://www.cff.org/Trials/Finder/details/10/Denufosol-Inhalation-Solution-in-People-With-Mild-CF-Lung-Disease-TIGER-2
https://www.cff.org/Trials/Finder/details/4/Infant-Study-of-Inhaled-Saline-ISIS
https://www.cff.org/Trials/Finder/details/147/Multiple-Dose-Safety-Study-of-SB-656933-in-People-with-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/36/KB001-A-in-people-with-CF-and-Pseudomonas-aeruginosa
https://www.cff.org/Trials/Finder/details/330/AquADEKs-2-Effects-of-an-antioxidant-enriched-multivitamin-on-inflammation-and-oxidative-stress-in-people-with-CF
https://www.cff.org/Trials/Finder/details/280/Phase-2-study-of-inhaled-Alpha-1-HC-in-people-with-CF
https://www.cff.org/Trials/Finder/details/90/PharmaNAC-Phase-2b-N-Acetylcysteine-Effects-in-CF
https://www.cff.org/Trials/Finder/details/13/Safety-Study-of-KB001-in-People-with-CF-and-Pseudomonas-aeruginosa
https://www.cff.org/Trials/Finder/details/6/Safety-Study-of-Azithromycin-in-Cystic-Fibrosis-Patients-Negative-for-P-aeruginosa
https://www.cff.org/Trials/Finder/details/27/Aztreonam-Lysinate-for-Inhalation-in-Individuals-who-Utilize-Inhaled-Tobramycin-Frequently-AIR-CF2
https://www.cff.org/Trials/Finder/details/28/Long-term-Safety-Study-of-Aztreonam-Lysinate-in-CF-Patients-with-P-aeruginosa-AIR-CF3
https://www.cff.org/Trials/Finder/details/29/Aztreonam-Lysinate-for-Inhalation-in-Cystic-Fibrosis-Patients-with-P-aeruginosa-AIR-CF1
https://www.cff.org/Trials/Finder/details/31/Tobramycin-Inhalation-Powder-Compared-to-TOBI-in-People-with-CF
https://www.cff.org/Trials/Finder/details/81/Aztreonam-Lysinate-for-Inhalation-in-Cystic-Fibrosis-Patients-with-Mild-Lung-Disease-and-P-aeruginosa-AIR-CF4
https://www.cff.org/Trials/Finder/details/82/Inhaled-Fosfomycin-Tobramycin-for-People-with-CF-and-P-aeruginosa
https://www.cff.org/Trials/Finder/details/374/IGNITE-Safety-and-effectiveness-of-gallium-nitrate-in-adults-with-cystic-fibrosis
https://www.cff.org/Trials/Finder/details/359/Tobramycin-Inhalation-Powder-TIP-Administered-Once-Daily-Continuously-Versus-TIP-Administered-Twice-a-Day-Cycled
https://www.cff.org/Trials/Finder/details/283/OPTIMIZE-Phase-3-study-of-tobramycin-solution-for-inhalation-with-and-without-azithromycin
https://www.cff.org/Trials/Finder/details/295/Aztreonam-for-Inhalation-Solution-AZLI-taken-in-a-Continuous-Alternating-Therapy-Regimen-for-the-Treatment-of-Chronic-Pseudomonas-aeruginosa-lung-infections-in-people-with-CF
https://www.cff.org/Trials/Finder/details/275/Arikace-for-Nontuberculous-Mycobacteria-NTM
https://www.cff.org/Trials/Finder/details/281/Tobramycin-Inhalation-Powder-TIP-in-People-with-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/271/PALS-Aztreonam-Inhalation-Solution-AZLI-Safety-Study-in-Children-with-CF-and-Chronic-Pseudomonas-Aeruginosa
https://www.cff.org/Trials/Finder/details/266/Aztreonam-AZLI-in-Infants-and-Children-with-CF-and-New-Onset-Pseudomonas-Aeruginosa
https://www.cff.org/Trials/Finder/details/259/Early-Treatment-of-New-Onset-of-Methicillan-Resistant-Staphylococcus-Aureus-MRSA-Growth-in-Respiratory-Culture
https://www.cff.org/Trials/Finder/details/238/Levofloxacin-Inhalation-Solution-Aeroquin-compared-to-TOBI-in-people-with-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/224/Persistent-Methicillin-Resistant-Staphylococcus-Aureus-MRSA-Growth-in-Respiratory-Culture
https://www.cff.org/Trials/Finder/details/192/Levofloxacin-Inhalation-Solution-Aeroquin-compared-to-placebo-in-people-with-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/32/Amikacin-for-Inhalation-Transave
https://www.cff.org/Trials/Finder/details/5/Azithromycin-in-patients-with-CF-who-are-culture-negative-for-Pseudomonas-aeruginosa
https://www.cff.org/Trials/Finder/details/110/Biomarkers-of-Pulmonary-Exacerbation-in-Patients-with-CF
https://www.cff.org/Trials/Finder/details/187/AZLI-Inhaled-Aztreonam-for-People-with-Cystic-Fibrosis-and-Chronic-Burkholderia-Infection
https://www.cff.org/Trials/Finder/details/1/Early-Pseudomonas-Infection-Control-EPIC
https://www.cff.org/Trials/Finder/details/91/Inhaled-Levofloxacin-MP-376-in-CF-Patients-with-P-aeruginosa-Phase-2-Study
https://www.cff.org/Trials/Finder/details/22/Study-of-delayed-released-pancrelipase-capsules-in-people-with-CF-and-pancreatic-insufficiency
https://www.cff.org/Trials/Finder/details/470/ASSURE-Study-of-Relizorb-in-people-with-CF-who-receive-enteral-tube-feeding
https://www.cff.org/Trials/Finder/details/419/Study-of-in-line-digestive-enzyme-cartridge-Relizorb-in-people-with-CF-who-are-currently-receiving-enteral-tube-feedings
https://www.cff.org/Trials/Finder/details/410/SOLUTION-Study-of-Liprotamase-in-people-with-CF
https://www.cff.org/Trials/Finder/details/332/Burlulipase-in-People-with-CF-and-Pancreatic-Insufficiency
https://www.cff.org/Trials/Finder/details/18/Pancrecarb-MS-16-in-children-and-adults-with-CF
https://www.cff.org/Trials/Finder/details/116/Study-of-Pancrease-MT-Capsules-in-People-with-CF-and-Pancreatic-Insufficiency
https://www.cff.org/Trials/Finder/details/20/DIGEST-S-ALTU-135-for-the-treatment-of-CF-related-exocrine-pancreatic-insufficiency
https://www.cff.org/Trials/Finder/details/17/Safety-and-efficacy-of-Eurand-PEP-Microtabs-in-pediatric-patients-with-CF-related-pancreatic-insufficiency
https://www.cff.org/Trials/Finder/details/23/Use-of-Utrase-MT-12-Enzymes-in-Young-Children-with-CF-Related-Pancreatic-Insufficiency
https://www.cff.org/Trials/Finder/details/11/Efficacy-and-Safety-of-Ultrase-MT20-in-Children-with-CF-and-Pancreatic-Insufficiency
https://www.cff.org/Trials/Finder/details/181/Efficacy-and-safety-of-pancrelipase-delayed-release-capsules-in-young-children-with-CF
https://www.cff.org/Trials/Finder/details/19/DIGEST-E-Efficacy-and-safety-of-ALTU-135-in-patients-with-CF-related-exocrine-pancreatic-insufficiency
https://www.cff.org/Trials/Finder/details/16/Safety-and-effectiveness-of-the-Eurand-pancreatic-enzyme-supplement-in-people-with-CF
https://www.cff.org/Trials/Finder/details/21/Phase-3-Study-of-the-Safety-and-Effectiveness-of-ULTRASE-MT20-for-Pancreatic-Insufficiency
https://www.cff.org/Trials/Finder/details/61/Effects-of-a-behavioral-intervention-on-growth-in-preschoolers-with-CF
https://www.cff.org/Trials/Finder/details/178/iCARE-study-I-Change-Adherence-and-Raise-Expectations-Study
https://www.cff.org/Trials/Finder/details/351/STOP-Standardized-Treatment-of-Pulmonary-Exacerbations-Pilot-Study
https://www.cff.org/Trials/Finder/details/354/TOBI-Podhaler-Usability-Study
https://www.cff.org/Trials/Finder/details/349/Observational-Study-in-Children-6-Years-and-Up-who-have-the-R117H-or-other-non-G551D-gating-mutation
https://www.cff.org/Trials/Finder/details/285/Observational-Study-in-People-with-CF-with-the-G551D-mutation
https://www.cff.org/Trials/Finder/details/269/BONUS-Baby-Observational-and-Nutrition-Study
https://www.cff.org/Trials/Finder/details/254/Management-of-Bacterial-Air-Contamination-in-CF-Clinics
https://www.cff.org/Trials/Finder/details/2/Longitudinal-Assessment-of-Risk-Factors-for-and-Impact-of-Pseudomonas-aeruginosa-and-Early-Anti-Pseudomonal-Treatment-in-Children-with-CF
https://www.cff.org/Trials/Finder/details/39/Antimicrobial-Resistance-in-CF
https://www.cff.org/Trials/Finder/details/171/Characterization-of-MRSA-infection-colonization-in-CF
https://www.cff.org/Trials/Finder/details/105/Genetic-Modifiers-of-Cystic-Fibrosis-Sibling-Study
https://www.cff.org/Trials/Finder/details/109/Depression-and-Anxiety-in-CF-Patients-and-Caregivers
https://www.cff.org/Trials/Finder/details/278/Home-Monitoring-of-Lung-Function
https://www.cff.org/Trials/Finder/details/210/Tiotropium-Bromide-Spiriva-Safety-and-Effectiveness-in-People-with-Cystic-Fibrosis
https://www.cff.org/Trials/Finder/details/115/Effect-of-Tiotropium-Bromide-Spiriva-in-People-with-CF
https://www.cff.org/Trials/Finder/details/93/Effect-of-insulin-or-repaglinide-on-body-weight-and-pulmonary-function-in-patients-with-CF-related-diabetes